PMID- 38244518
OWN - NLM
STAT- MEDLINE
DCOM- 20240208
LR  - 20240208
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 128
DP  - 2024 Feb 15
TI  - The role of dendritic cells in cancer immunity and therapeutic strategies.
PG  - 111548
LID - S1567-5769(24)00066-3 [pii]
LID - 10.1016/j.intimp.2024.111548 [doi]
AB  - Dendritic cells (DCs) are asserted as the most potent antigen-presenting cells 
      (APCs) that orchestrate both innate and adaptive immunity, being extremely 
      effective in the induction of robust anti-cancer T cell responses. Hence, the 
      modulation of DCs function represents an attractive target for improving cancer 
      immunotherapy efficacy. A better understanding of the immunobiology of DCs, the 
      interaction among DCs, immune effector cells and tumor cells in tumor 
      microenvironment (TME) and the latest advances in biomedical engineering 
      technology would be required for the design of optimal DC-based immunotherapy. In 
      this review, we focus on elaborating the immunobiology of DCs in healthy and 
      cancer environments, the recent advances in the development of enhancing 
      endogenous DCs immunocompetence via immunomodulators as well as DC-based 
      vaccines. The rapidly developing field of applying nanotechnology to improve 
      DC-based immunotherapy is also highlighted.
CI  - Copyright (c) 2024 Elsevier B.V. All rights reserved.
FAU - Tai, Yunze
AU  - Tai Y
AD  - Department of Laboratory Medicine, West China Hospital, Sichuan University, 
      Chengdu 610041, China.
FAU - Chen, Man
AU  - Chen M
AD  - Hebei Yanda Lu Daopei Hospital, Langfang 065201, China.
FAU - Wang, Fang
AU  - Wang F
AD  - Department of Medical Laboratory, The Second Affiliated Hospital of Guizhou 
      Medical University, Kaili, Guizhou 556000, China.
FAU - Fan, Yu
AU  - Fan Y
AD  - Department of Urology, National Clinical Research Center for Geriatrics and Organ 
      Transplantation Center, West China Hospital, Sichuan University, No. 37 Guoxue 
      Xiang, Chengdu 610041, China.
FAU - Zhang, Junlong
AU  - Zhang J
AD  - Department of Laboratory Medicine, West China Hospital, Sichuan University, 
      Chengdu 610041, China.
FAU - Cai, Bei
AU  - Cai B
AD  - Department of Laboratory Medicine, West China Hospital, Sichuan University, 
      Chengdu 610041, China.
FAU - Yan, Lin
AU  - Yan L
AD  - Department of Laboratory Medicine, West China Hospital, Sichuan University, 
      Chengdu 610041, China.
FAU - Luo, Yao
AU  - Luo Y
AD  - Department of Laboratory Medicine, West China Hospital, Sichuan University, 
      Chengdu 610041, China. Electronic address: luoyao@scu.edu.cn.
FAU - Li, Yi
AU  - Li Y
AD  - Department of Laboratory Medicine, West China Hospital, Sichuan University, 
      Chengdu 610041, China. Electronic address: liyiscu@126.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240119
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Humans
MH  - Dendritic Cells
MH  - *Neoplasms
MH  - Immunotherapy
MH  - Adaptive Immunity
MH  - Adjuvants, Immunologic
MH  - *Cancer Vaccines
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - Cancer
OT  - Dendritic cells
OT  - Immunotherapy
OT  - Nanotherapy
OT  - Tumor microenvironment
OT  - Vaccines
EDAT- 2024/01/21 00:42
MHDA- 2024/02/08 06:43
CRDT- 2024/01/20 18:14
PHST- 2023/11/07 00:00 [received]
PHST- 2024/01/03 00:00 [revised]
PHST- 2024/01/12 00:00 [accepted]
PHST- 2024/02/08 06:43 [medline]
PHST- 2024/01/21 00:42 [pubmed]
PHST- 2024/01/20 18:14 [entrez]
AID - S1567-5769(24)00066-3 [pii]
AID - 10.1016/j.intimp.2024.111548 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2024 Feb 15;128:111548. doi: 10.1016/j.intimp.2024.111548. 
      Epub 2024 Jan 19.